- Home
- EWTX vs WNS Comparison
EWTX vs WNS Comparison
Compare EWTX & WNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- WNS
- Stock Information
- Founded
- EWTX 2017
- WNS 1996
- Country
- EWTX United States
- WNS India
- Employees
- EWTX N/A
- WNS N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- WNS Business Services
- Sector
- EWTX Health Care
- WNS Consumer Discretionary
- Exchange
- EWTX Nasdaq
- WNS Nasdaq
- Market Cap
- EWTX 2.3B
- WNS 2.4B
- IPO Year
- EWTX 2021
- WNS N/A
- Fundamental
- Price
- EWTX $20.13
- WNS $66.58
- Analyst Decision
- EWTX Buy
- WNS Buy
- Analyst Count
- EWTX 8
- WNS 9
- Target Price
- EWTX $45.38
- WNS $62.89
- AVG Volume (30 Days)
- EWTX 1.5M
- WNS 625.9K
- Earning Date
- EWTX 03-03-2025
- WNS 04-24-2025
- Dividend Yield
- EWTX N/A
- WNS N/A
- EPS Growth
- EWTX N/A
- WNS N/A
- EPS
- EWTX N/A
- WNS 2.70
- Revenue
- EWTX N/A
- WNS $1,315,456,000.00
- Revenue This Year
- EWTX N/A
- WNS N/A
- Revenue Next Year
- EWTX N/A
- WNS $6.96
- P/E Ratio
- EWTX N/A
- WNS $22.79
- Revenue Growth
- EWTX N/A
- WNS 1.07
- 52 Week Low
- EWTX $14.90
- WNS $39.85
- 52 Week High
- EWTX $38.12
- WNS $70.31
- Technical
- Relative Strength Index (RSI)
- EWTX 28.86
- WNS 65.26
- Support Level
- EWTX $21.58
- WNS $59.70
- Resistance Level
- EWTX $25.36
- WNS $65.26
- Average True Range (ATR)
- EWTX 1.99
- WNS 2.88
- MACD
- EWTX -0.38
- WNS 0.05
- Stochastic Oscillator
- EWTX 2.67
- WNS 70.33
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About WNS WNS (Holdings) Limited Sponsored ADR (Jersey)
WNS (Holdings) Ltd is a Global provider of business process management (BPM) services, offering comprehensive data, voice, analytical, and business transformation services with a blended onshore, nearshore and offshore delivery model. The company's segment includes Banking/Financial Services, and Insurance; Travel, Shipping/Logistics, and Utilities; Manufacturing/Retail/Consumer, Hi-tech/Professional Services, and Procurement; Healthcare/Life Sciences. Geographically the company generates the majority of its revenue from North America (primarily the US), followed by the UK. The company also has a presence in Australia, Europe (excluding the UK), and South Africa.